Filing Flows › Coherus Oncology (CHRS) › Q1 2026 › vs Q1 2025
Coherus Oncology (CHRS) Q1 2026 vs Q1 2025 (year over year)
Coherus Oncology's revenue rose $4.7M (+62%) from $7.6M in Q1 2025 to $12.3M in Q1 2026. The biggest changes: Toripalimab +$4.5M (+61%); Other revenue +$256K (+102%).
Coherus Oncology, Q1 2026: revenue $12.3M (+62% year over year), operating margin -293.7%, net loss $38.3M, operating cash flow −$57.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Toripalimab | $11.8M | $7.3M | $4.5M | +61% |
| Other revenue | $507K | $251K | $256K | +102% |
| Revenue | $12.3M | $7.6M | $4.7M | +62% |
| Net loss | $38.3M | $56.6M | −$18.2M | -32% |
| Costs & expenses | $50.6M | $64.2M | −$13.5M | -21% |
| Operating costs | $48.5M | $53.0M | −$4.6M | -9% |
| Interest & other, net | $784K | $2.0M | −$1.2M | -60% |
| Income tax | $1.4M | $9.2M | −$7.8M | -85% |
| Cost of revenue | $3.8M | $2.7M | $1.2M | +44% |
| Research & development | $21.5M | $24.4M | −$2.8M | -12% |
| SG&A | $23.1M | $26.0M | −$2.9M | -11% |
| Operating cash sources | $61.2M | $31.6M | $29.6M | +94% |
| Depreciation & amortization | $881K | $400K | $481K | +120% |
| Share-based compensation | $2.4M | $5.4M | −$3.0M | -56% |
| Cash used in operations | $57.9M | $25.8M | $32.1M | +124% |
| Net loss absorbed | $38.3M | $56.6M | −$18.2M | -32% |
| Working capital & other | $22.8M | −$25.0M | $47.8M | — |
Questions
How much did Coherus Oncology's revenue grow year over year in Q1 2026?
Coherus Oncology's revenue rose $4.7M (+62%) from $7.6M in Q1 2025 to $12.3M in Q1 2026.
What drove Coherus Oncology's revenue change in Q1 2026?
Toripalimab +$4.5M (+61%); Other revenue +$256K (+102%).